CYTOSORBENTS MEDICAL INC — Department of Defense SBIR Phase I: AFX235-CSO1
CYTOSORBENTS MEDICAL INC — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $74,918. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code AFX235-CSO1 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $74,918
- Agency
- Department of Defense · Air Force
- Program / Phase
- SBIR · Phase I
- Topic
- AFX235-CSO1
- Solicitation
- X23.5
- NAICS
- —
- Place of performance
- NJ
- Period
- 2023-05-12 → 2023-08-10
Description
Joint injuries, whether sustained during training or in the field, are a major source of lost duty days in the military. The immediate effects are severe pain, swelling and inflammation, which can compromise warfighter readiness and result in significant